- June 1, 2021Annovis Bio’s ANVS401 Improves Speed and Accuracy in Alzheimer’s and in Parkinson’s Patients
- May 28, 2021Annovis Bio Engages Global Executive Search Leader Spencer Stuart to Expand its Board and Management Team
- May 27, 2021Annovis Bio, Inc. Announces Closing of $50 Million Public Offering
- October 01, 2019Axonal Transport and Neurological Disease
- May 21, 2019How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?
- April 30, 2019After amyloid failures, it’s time to take a new tack for treating Alzheimer’s
Back to Top